Al-Hussaini M, Stockman A, Foster H, McCluggage W G
Department of Pathology, Royal Group of Hospitals Trust, Belfast, UK.
Histopathology. 2004 Feb;44(2):109-15. doi: 10.1111/j.1365-2559.2004.01787.x.
It has been suggested that WT-1 is helpful in distinguishing a primary ovarian serous carcinoma (OSC) from a primary uterine serous carcinoma (USC). Since both neoplasms are often disseminated at diagnosis and since USC often spreads to the ovary and vice versa, it may be difficult to ascertain the primary site. This is important, since adjuvant therapies for OSC and USC may differ. WT-1 staining patterns also differ between OSC and ovarian endometrioid carcinoma and so it is possible that WT-1 may assist in the distinction of these two neoplasms, which is sometimes problematic, especially with poorly differentiated tumours. This study aims to document the value of WT-1 in these settings. Cases of ovarian borderline serous tumour, primary peritoneal serous carcinoma (PPSC) and uterine endometrioid carcinoma were also studied.
Cases of OSC (n = 38), USC (n = 25) (in five of these cases there was also a component of endometrioid adenocarcinoma), ovarian endometrioid carcinoma (n = 13), uterine endometrioid carcinoma (n = 7), ovarian borderline serous tumour (n = 16) and PPSC (n = 6) were stained with WT-1. Cases were scored on a scale of 0-3, depending on the percentage of positive cells. The intensity of staining was scored as weak, moderate or strong. There was positive nuclear staining of 36 of 38 (94.7%) OSC with WT-1. In most OSC (68.4%), >50% of cells stained positively and staining was usually strong. Five of 25 (20%) USC were positive with only two cases exhibiting staining of >50% of cells. All primary ovarian and uterine endometrioid carcinomas were negative. All PPSC were positive, usually with diffuse strong immunoreactivity. Fourteen of 16 borderline serous tumours exhibited positivity with WT-1.
WT-1 is useful in distinguishing OSC (characteristically diffuse strong nuclear positivity) from USC (characteristically negative). However, rarely OSC is negative and occasional cases of USC are positive. WT-1 may also be helpful in differentiating poorly differentiated OSC from poorly differentiated ovarian endometrioid carcinoma.
有人提出WT-1有助于鉴别原发性卵巢浆液性癌(OSC)和原发性子宫浆液性癌(USC)。由于这两种肿瘤在诊断时常常已经发生播散,且USC常转移至卵巢,反之亦然,因此可能难以确定原发部位。这一点很重要,因为OSC和USC的辅助治疗可能不同。WT-1的染色模式在OSC和卵巢子宫内膜样癌之间也存在差异,所以WT-1有可能有助于鉴别这两种肿瘤,这有时会存在问题,尤其是对于低分化肿瘤。本研究旨在记录WT-1在这些情况下的价值。还对卵巢交界性浆液性肿瘤、原发性腹膜浆液性癌(PPSC)和子宫子宫内膜样癌病例进行了研究。
对OSC病例(n = 38)、USC病例(n = 25)(其中5例还伴有子宫内膜样腺癌成分)、卵巢子宫内膜样癌病例(n = 13)、子宫子宫内膜样癌病例(n = 7)、卵巢交界性浆液性肿瘤病例(n = 16)和PPSC病例(n = 6)进行WT-1染色。根据阳性细胞百分比,将病例按0 - 3分进行评分。染色强度分为弱、中、强。38例OSC中有36例(94.7%)WT-1核染色阳性。在大多数OSC(68.4%)中,>50%的细胞染色阳性,且染色通常为强阳性。25例USC中有5例(20%)阳性,只有2例显示>50%的细胞染色。所有原发性卵巢和子宫子宫内膜样癌均为阴性。所有PPSC均为阳性,通常为弥漫性强免疫反应。16例交界性浆液性肿瘤中有14例WT-1呈阳性。
WT-1有助于鉴别OSC(典型表现为弥漫性强核阳性)和USC(典型表现为阴性)。然而,OSC极少呈阴性,偶尔有USC病例呈阳性。WT-1也可能有助于鉴别低分化OSC和低分化卵巢子宫内膜样癌。